FastTest. You ve read the book now test yourself
|
|
|
- Tyler Davis
- 10 years ago
- Views:
Transcription
1 FastTest You ve read the book now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. Please refer back to relevant sections of the book to address any areas of uncertainty. Which of the following statements are correct? Note: there may be more than one correct answer per question.
2 1 Epidemiology and pathophysiology 1. In terms of the incidence of psoriasis: a) chronic plaque psoriasis is the most common form of the disease b) there is considerable interracial variation c) the peak age of onset is years d) men are more commonly affected than women 2. There are two types of chronic plaque psoriasis type I (common) and type II (uncommon). a) Type 1 tends to occur in young adults b) A positive family history is uncommon in patients with type I disease c) Type I disease tends to be mild and localized d) Type I disease tends to run an irregular course
3 3. The pathogenesis of psoriasis involves the interplay between environmental and genetic factors. a) Over 50% of patients with psoriasis have a known family history of the disease b) Nutritional deficiencies can be an important environmental trigger c) Excessive alcohol intake is associated with disease deterioration d) The major psoriasis genetic locus, PSORS1, contributes up to 50% of the genetic risk
4 2 Clinical presentation 4. Important clues to the diagnosis of psoriasis include a history of: a) atopic asthma and/or eczema b) persistent dandruff and/or scaling in the ears c) skin allergies d) joint problems e) autoimmune disease 5. Typically, chronic plaque psoriasis is: a) discoid in shape b) not itchy c) symmetrically distributed d) more common on thinner areas of skin
5 6. Comorbidities associated with psoriasis include: a) Crohn s disease b) lymphoma c) eczema d) metabolic syndrome e) cardiovascular disease
6 3 Differential diagnoses 7. A number of dermatological conditions may be confused with psoriasis. a) Mycological specimens should be taken from skin, hair or nails to differentiate Tinea infection (ringworm) from psoriasis b) The Koebner phenomenon is found in lichen planus but not in psoriasis c) A skin biopsy should be taken to differentiate psoriasis from hyperkeratotic forms of eczema on the hands and feet d) Contact dermatitis is seldom symmetrical and is more pruritic than psoriasis
7 8. Which of the following is/are psoriasis? (a) (b) (c) (d) (e) (f)
8 4 General management approach 9. Before starting treatment, useful advice for patients includes: a) Reassurance that early treatment can prevent the disease from becoming more severe b) Details of local side effects such as irritation or staining c) The benefits of active treatment, even for mild disease d) Information about stress reduction and management e) A warning that treatment is likely to be lengthy
9 10. Psoriasis is a chronic disease that requires long-term therapy. a) Relapse is likely if therapy is discontinued b) Longer-term remissions can be achieved with combined or rotational therapies than with any individual modality c) Combination therapy increases drug-related toxicity d) More toxic agents can be used to clear psoriasis followed by less toxic agents to maintain remission
10 5 Topical therapy 11. Choice of formulation will depend on patient preference and the site/pattern of psoriasis. a) Lotions tend to be most suitable for use at flexural sites b) Creams are less greasy than ointments and are therefore often prescribed for the face c) Ointments tend to be the preferred formulation for plaque psoriasis on the body d) Topical agents are particularly useful for the treatment of nail psoriasis
11 12. Corticosteroids are an integral component of topical therapy (first-line therapy in the UK and USA for chronic plaque psoriasis). a) Continuous use of corticosteroids may lead to loss of efficacy b) On stopping corticosteroid therapy, rebound psoriasis and a more inflammatory form of the disease may develop c) Side effects include irreversible skin bleaching d) Moderate or severe atopic eczema may complicate the use of topical corticosteroids e) Corticosteroids should be used alternately or in rotation with non-steroid-based therapies
12 13. The vitamin D 3 analogs calcipotriol, tacalcitol and calcitriol are all effective in chronic plaque psoriasis (first-line therapy in the UK and Europe). a) Efficacy is comparable to that of topical corticosteroids with mid-to-high potency b) Local side effects include tachyphylaxis and skin staining c) Onset of action is quicker than that of topical corticosteroids d) These agents can be used in combination with corticosteroids, phototherapy or systemic agents
13 6 Phototherapy and photochemotherapy 14. Phototherapy involves whole-body exposure to artificial sources of ultraviolet (UV) radiation a) Phototherapy involves the application of UVA radiation to the epidermis b) Phototherapy is usually given once weekly c) Topical corticosteroids used concurrently with phototherapy may increase relapse rates d) Phototherapy is well tolerated during pregnancy
14 15. Photochemotherapy (PUVA) involves the application of a photosensitizing drug (methoxsalen) in combination with UVA radiation. a) PUVA is contraindicated in patients with localized recalcitrant disease (e.g. palmar plantar psoriasis) b) Remission rates with PUVA are inferior to most other forms of therapy c) Methoxsalen remains in the eye for up to 12 hours after ingestion, necessitating appropriate eye protection after treatment d) PUVA is associated with a significant long-term risk of skin cancer
15 7 Systemic therapy 16. With systemic therapy, the benefits of disease clearance must be balanced against the risk of short- and long-term side effects. a) Most systemic therapies are associated with immunosuppression b) Systemic retinoids should be not be used in combination with PUVA c) Women should be advised to avoid conception for up to a year after acitretin therapy d) With ciclosporin therapy, the more inflammatory the psoriasis the more dramatic the response 17. Methotrexate is the gold standard of systemic therapy. a) Folic acid supplementation should be given concurrently with methotrexate b) Abrupt discontinuation of methotrexate may destabilize the psoriasis, which can lead to inflammatory flares c) Methotrexate is contraindicated during pregnancy or breastfeeding d) Methotrexate can be administered orally, intramuscularly or subcutaneously
16 8 Receptor-targeted (biological) therapies 18. Biological therapy targets specific molecules involved in the immunopathogenesis of psoriasis. a) At present, biological therapy is only licensed for patients with psoriatic joint disease b) Currently available biological agents are all administered by injection c) The biological agents used to treat psoriasis are associated with significant hepatotoxicity that warrants careful monitoring d) Biological therapies potentially reduce cardiovascular events in the psoriasis population
17 9 Psoriatic arthritis 19. Psoriatic arthritis is a common autoimmune inflammatory condition affecting the joints and entheses of patients with psoriasis. a) Onset of the disease is most common in people in their 20s and 30s b) Psoriatic arthritis, when it occurs, usually emerges before the appearance of skin lesions, which makes diagnosis difficult c) Women are more commonly affected than men d) Blood testing for rheumatoid factor is usually positive
18 20. In the treatment of psoriatic arthritis: a) long-term therapy with COX-2 inhibitors is a feasible option in patients with mild disease b) both methotrexate and ciclosporin have been shown to yield clinically significant improvements in joint disease c) biological therapies have been shown to inhibit the progression of structural damage d) biological therapies have been shown to significantly reduce fatigue, and improve function and quality of life
19 Thank you for taking this FastTest. There is no final score or certificate, but by reinforcing your understanding you have enhanced your clinical skills and practice. If you found the book useful, please spread the word about Fast Facts to your colleagues, students and patients.
X-Plain Psoriasis Reference Summary
X-Plain Psoriasis Reference Summary Introduction Psoriasis is a long-lasting skin disease that causes the skin to become inflamed. Patches of thick, red skin are covered with silvery scales. It affects
Psoriasis Treatment Transition Pathway
Psoriasis Treatment Transition Pathway A Treatment Support Tool Adapted from Circle Nottingham NHS Treatment Centre Psoriasis Pathway (under consultation) with support from Abbvie Ltd Treatment Pathways
Psoriasis. Psoriasis. Mark A. Bechtel, M.D. Director of Dermatology The Ohio State University College of Medicine
Psoriasis Mark A. Bechtel, M.D. Director of Dermatology The Ohio State University College of Medicine Psoriasis Psoriasis is a chronic skin disorder resulting from a polygenic predisposition combined with
How To Take Methotrexate By Injection
How To Take Methotrexate By Injection 1 how long does it take for methotrexate to work for abortion 2 methotrexate 15 mg hair loss 3 methotrexate injection dosage for rheumatoid arthritis 4 order methotrexate
Psoriasis. Student's Name. Institution. Date of Submission
Running head: PSORIASIS Psoriasis Student's Name Institution Date of Submission PSORIASIS 1 Abstract Psoriasis is a non-contagious chronic skin disease that is characterized by inflammatory and multiplying
Is Monotherapy Treatment of Etanercept Effective Against Plaque Psoriasis?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2011 Is Monotherapy Treatment of Etanercept
Cutaneous Lymphoma FAST FACTS
Cutaneous Lymphoma FAST FACTS What is Cutaneous Lymphoma? Cutaneous lymphomas are types of non-hodgkin s lymphomas (NHL) that originate in the lymphocytes (white blood cells). Unlike most other types of
Additional information >>> HERE <<< How To scalp psoriasis treatment philippines Scam or Work?
Additional information >>> HERE http://urlzz.org/psoriasis7/pdx/fph1
Treatment options a simple guide
Guide Treatment options a simple guide To decide which treatment is right for you, a good starting point is to know what options you have and to understand the pros and cons of each one. People respond
How To Choose A Biologic Drug
North Carolina Rheumatology Association Position Statements I. Biologic Agents A. Appropriate delivery, handling, storage and administration of biologic agents B. Indications for biologic agents II. III.
PSORIASIS AND ITS. Learn how vitamin D medications play an important role in managing plaque psoriasis
PLAQUE PSORIASIS AND ITS TREATMENTS Learn how vitamin D medications play an important role in managing plaque psoriasis 2 Understanding Plaque Psoriasis WHAT CAUSES PLAQUE PSORIASIS? No one knows exactly
FastTest. You ve read the book... ... now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
Topical Tacrolimus or Pimecrolimus for the treatment of mild, moderate or severe atopic eczema. Effective Shared Care Agreement
Topical Tacrolimus or Pimecrolimus for the treatment of mild, moderate or severe atopic eczema. Effective Shared Care Agreement A Copy of this page signed by all three parties should be retained in the
Summary of the risk management plan (RMP) for Otezla (apremilast)
EMA/741412/2014 Summary of the risk management plan (RMP) for Otezla (apremilast) This is a summary of the risk management plan (RMP) for Otezla, which details the measures to be taken in order to ensure
Methotrexate Dose For Juvenile Rheumatoid Arthritis
Methotrexate Dose For Juvenile Rheumatoid Arthritis should i take methotrexate for my ra methotrexate 50 mg/ml methotrexate sodium 2.5mg tablets what is the usual dosage of methotrexate for ra methotrexate
www.healthoracle.org 1
How does hair grow and should it recycle? A single hair follicle grows its hair strand over a period of four to six years (the anagen phase). It then rests for two to four months (the telogen phase), after
Evidence-based Management of Rheumatoid Arthritis (2009)
CPLD reviews its distance learning programmes every twelve months to ensure currency. This update has been produced by an expert and should be read in conjunction with the Evidencebased Management of distance
National Medicines Information Centre ST. JAMES S HOSPITAL DUBLIN 8 TEL 01-4730589 or 1850-727-727 FAX 01-4730596 E-Mail: nmic@stjames.
VOLUME 6 NUMBER 6 2000 PSORIASIS National Medicines Information Centre ST. JAMES S HOSPITAL DUBLIN 8 TEL 01-4730589 or 1850-727-727 FAX 01-4730596 E-Mail: [email protected] SUMMARY The aim of treatment is
TREATMENTS FOR MODERATE OR SEVERE PSORIASIS
TREATMENTS FOR MODERATE OR SEVERE PSORIASIS What are the aims of this leaflet? Patients with psoriasis are usually treated with creams and ointments, which are applied to the skin. These are discussed
Efficacy and Safety of Calcipotriol Ointment in Psoriasis Vulgaris - Experiences in Hong Kong
ORIGINAL ARTICLES Efficacy and Safety of Calcipotriol Ointment in Psoriasis Vulgaris - Experiences in Hong Kong Drs. C. W. Fung, L.Y. Chong, C.Y. Leung, C. N. Look, K.K. Lo, K. M. Ho Social Hygiene Service
TOPICAL TREATMENTS FOR PSORIASIS
TOPICAL TREATMENTS FOR PSORIASIS What are the aims of this leaflet? Patients with psoriasis are usually treated with preparations that are applied to the skin. This leaflet has been written to help you
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure
biologics for the treatment of psoriasis
How to contact us The Psoriasis Association Dick Coles House 2 Queensbridge Northampton NN4 7BF tel: 08456 760 076 (01604) 251 620 fax: (01604) 251 621 email: [email protected] www.psoriasis-association.org.uk
Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
Brochure More information from http://www.researchandmarkets.com/reports/3128342/ Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023 Description: Methotrexate (Rheumatoid Arthritis)
Prescribing advice for the management and treatment of psoriasis
Prescribing advice for the management and treatment of psoriasis This guidance contains suggested advice for the management and treatment of patients presenting with psoriasis. This guidance applies to
Biologic Treatments for Rheumatoid Arthritis
Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been
Department of Dermatology, Churchill Hospital PUVA Treatment
Oxford University Hospitals NHS Trust Department of Dermatology, Churchill Hospital PUVA Treatment information for patients CONTENTS What is PUVA 3 What conditions are treated with PUVA? 3 How is PUVA
Current Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists
Current Rheumatoid Arthritis Treatment Options: Update for Managed Care and Specialty Pharmacists 1. Which of the following matches of biologic targets that contribute to rheumatoid arthritis (RA) and
Phenotypes and Classification of Psoriasis
Rheumatology 2010 Birmingham 21 April 2010 Phenotypes and Classification of Psoriasis Christopher E.M. Griffiths Abbott Centocor Incyte Galderma Janssen-Cilag Leo Pharma Lynxx Novartis Pfizer Schering-Plough
Common Skin Conditions in Children. Liz Moore and Emma King Dermatology Nurse Consultants
Common Skin Conditions in Children Liz Moore and Emma King Dermatology Nurse Consultants Diagnosis? Nummular Dermatitis Disc pattern rash (discoid eczema) Clearly demarcated edges Occurs at any age Can
Psoriasis: Controlled YOUR GUIDE TO BIOLOGICAL TREATMENTS FOR PLAQUE PSORIASIS
Psoriasis: Controlled YOUR GUIDE TO BIOLOGICAL TREATMENTS FOR PLAQUE PSORIASIS 2 Proudly supported by Disclaimer: Some photographs and models used in this booklet are for illustrative purposes only and
GP Symposium Dermatology Dr Seow Hoong Foo Dr Shireen Velangi March 6th 2014
Psoriasis : It s not just skin de eep NICE Guidelines and Quality Standards: a collaboration to deliver quality care GP Symposium Dermatology y p gy Dr Seow Hoong Foo Dr Shireen Velangi March 6th 2014
Psoriatic Arthritis www.arthritis.org.nz
Psoriatic Arthritis www.arthritis.org.nz Did you know? Arthritis affects one in six New Zealanders over the age of 15 years. Psoriatic arthritis usually appears in people between the ages of 30 to 50.
Psoriasis is a skin condition that causes scaly red patches on your skin. There's no cure for psoriasis, but there are treatments that can help.
Patient information from the BMJ Group Psoriasis What is it? What are the symptoms? How is it diagnosed? How common is it? What treatments work? What will happen? Questions to ask Psoriasis If you get
Treating psoriasis and psoriatic arthritis. A booklet for patients and carers
Treating psoriasis and psoriatic arthritis A booklet for patients and carers Picture credits Cover Stuart Neville Page 4 Dr P. Marazzi/Science Photo Library CNRI/Science Photo Library CID, ISM/Science
Professor Andrew Wright,
Professor Andrew Wright, Systemic treatments are drugs taken as tablets or injections that travel through the bloodstream, dampening down the immune system to reach and treat eczema all over the body.
subcutaneous initially every 4 weeks then every 12 weeks Coverage Criteria: Express Scripts, Inc. monograph dated 02/24/2010
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Humira (adalimumab subcutaneous injection) Commercial HMO/PPO/CDHP
Preetha selva et al. / International Journal of Phytopharmacology. 6(1), 2015, 42-46. International Journal of Phytopharmacology
International Journal of Phytopharmacology Journal homepage: www.onlineijp.com 42 e- ISSN 0975 9328 Print ISSN 2229 7472 IJP A CLINICAL STUDY TO EVALUATE THE EFFECT OF TOPICAL TAZAROTENE IN THE TREATMENT
CLINICAL BRIEFS. Considerations for the Clinical Assessment of the Patient With Plaque Psoriasis. By Amy Krajacic
CLINICAL BRIEFS Considerations for the Clinical Assessment of the Patient With Plaque Psoriasis By Amy Krajacic Senior Medical Editor, Custom Publications MediMedia USA, Yardley, Pa. A review of recently
Top 10 Psoriasis Treatment Tips
Top 10 Psoriasis Treatment Tips Steven R. Feldman, MD, PhD Professor of Dermatology, Pathology & Social Sciences Director, Psoriasis Treatment Center Wake Forest University School of Medicine Winston-Salem,
completenutrition I R E L A N D The Role of Fulvic Acid in Skin Health By Peter Gouge BSc (Hons) Nutrition, RNutr
The Role of Fulvic Acid in Skin Health By Peter Gouge BSc (Hons) Nutrition, RNutr Copyright 2009 The skin is the largest organ in the Human body and along with this it is our indicator of poor health.
MEDICATION GUIDE STELARA
MEDICATION GUIDE STELARA (stel ar a) (ustekinumab) Injection What is the most important information I should know about STELARA? STELARA is a medicine that affects your immune system. STELARA can increase
VITILIGO Charles Camisa, MD 1/24/12. Vitiligo is a common autoimmune skin disease that causes gradual loss of the natural
VITILIGO Charles Camisa, MD 1/24/12 What is vitiligo? Vitiligo is a common autoimmune skin disease that causes gradual loss of the natural brown pigment in the skin called melanin. It affects about 1%
Results of the first clinical study on a new treatment for Psori asis: the T.M.S.T. method
MINERAL MOR LTD Results of the first clinical study on a new treatment for Psori asis: the TMST method Marco Harari MD 12122012 Conclusions: 1 No side effects were recorded during the 5week study period
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Multiple Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Multiple Technology Appraisal Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional
CAN-FITE BIOPHARMA LTD.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month
Guidelines of care for the management of psoriasis and psoriatic arthritis
FROM THE ACADEMY Guidelines of care for the management of psoriasis and psoriatic arthritis Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations
Once the immune system is triggered, cells migrate from the blood into the joints and produce substances that cause inflammation.
HealthExchange Points For Your Joints An Arthritis Talk Howard Epstein, MD Orthopaedic & Rheumatologic Institute Rheumatic & Immunologic Disease Cleveland Clinic Beachwood Family Health & Surgery Center
Guideline for the use of Biological Therapies in the Treatment of Psoriasis
1 Date of Production: March1 st 2011 Date of 1 st review: July 10 th 2015 Date for next review: March1 st 2018 Local Contact Dermatology Consultant Shanti Ayob Patient group to which this applies: Patients
Immune Modulating Drugs Prior Authorization Request Form
Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:
Guidelines of care for the management of psoriasis and psoriatic arthritis
FROM THE ACADEMY Guidelines of care for the management of psoriasis and psoriatic arthritis Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations
Rheumatoid Arthritis monitoring of DMARDs
www.bpac.org.nz keyword: DMARDS Rheumatoid Arthritis monitoring of DMARDs Key reviewers: Professor John Highton, Head of Section, Department of Medical and Surgical Sciences, Dunedin School of Medicine,
Original Policy Date
MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer
MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists
MEDICAL ASSISTANCE HBOOK `I. Requirements for Prior Authorization of Cytokine and CAM Antagonists A. Prescriptions That Require Prior Authorization All prescriptions for Cytokine and CAM Antagonists must
Psoriatic arthritis FACTSHEET
1 What is psoriatic arthritis? Psoriatic arthritis (PsA) is a disease where joints around the body become inflamed and sore. It can make moving about difficult and painful. People who have PsA also have
Autoimmune Diseases More common than you think Randall Stevens, MD
Autoimmune Diseases More common than you think Randall Stevens, MD picture placeholder Autoimmune Diseases More than 60 different disorders Autoimmune disorders (AID) diseases caused by the immune system
INITIATING ORAL AUBAGIO (teriflunomide) THERAPY
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been
Rheumatoid Arthritis
What is Rheumatoid Arthritis? Rheumatoid Arthritis (RA) is a chronic and systemic disease that causes pain, stiffness, swelling, and limitation in the motion and function of multiple joints. Though joints
PACKAGE LEAFLET: INFORMATION FOR THE USER. VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution. Cyanocobalamin
PACKAGE LEAFLET: INFORMATION FOR THE USER VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution Cyanocobalamin Read all of this leaflet carefully before you start using this medicine because
Drug Therapy Guidelines: Humira (adalimumab)
Drug Therapy Guidelines: Humira (adalimumab) Effective Date: 5/1/08 Committee Review Date: 1/6/01, 9/18/01, 1/15/02, 1/7/03, 1/20/04, 1/18/05, 12/7/05, 10/15/06, 7/2/07, 11/5/07, 3/25/08 Policy Statements:
Guidelines of care for the management of psoriasis and psoriatic arthritis
FROM THE ACADEMY Guidelines of care for the management of psoriasis and psoriatic arthritis Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies Alan Menter,
MEDICATION GUIDE. PROTOPIC [pro-top-ik] (tacrolimus) Ointment 0.03% Ointment 0.1%
MEDICATION GUIDE PROTOPIC [pro-top-ik] (tacrolimus) Ointment 0.03% Ointment 0.1% Read the Medication Guide every time you or a family member gets PROTOPIC Ointment. There may be new information. This Medication
1g cream or ointment contains 1 mg methylprednisolone aceponate.
CONSUMER MEDICINE INFORMATION ADVANTAN 1g cream or ointment contains 1 mg methylprednisolone aceponate. What is in this leaflet Please read this leaflet carefully before you start using ADVANTAN. It will
Core therapeutic areas
Core therapeutic areas Platforms for growth Luke Miels, Executive Vice President, Global Portfolio & Product Strategy and Corporate Affairs Current business is led by core therapeutic areas Sales 9M 2014
Treating your skin condition with narrowband ultraviolet B radiation (NB-UVB)
Treating your skin condition with narrowband ultraviolet B radiation (NB-UVB) Your doctor has referred you to the Dowling Day Treatment Centre for a course of narrow band ultraviolet treatment for your
How To Treat Psoriasis With Omega 3 Fatty Acids
CAN PSORIASIS TREATMENT BE AIDED BY OMEGA-3 FATTY ACIDS? Brittney Urban Psoriasis Chronic skin disease Cell life cycle build up Can be disabling Symptoms: Red patches with silvery scales Dry, cracked skin
Nail Psoriasis. A positive approach. to psoriasis and. psoriatic arthritis
Nail Psoriasis A positive approach to psoriasis and psoriatic arthritis What is psoriasis? Psoriasis (Ps) is a long-term (chronic) scaling disease of the skin, which affects 2% 3% of the UK population.
First Name. Profession. Weight lbs. Weight 1 year ago lbs. Min. Adult Weight lbs. at age Maximum Weight lbs. at age
Date Time Dietary consultation involves a health profile whose purpose is not to establish a diagnosis, but rather to determine a client's health status in order to guide his or her weight loss plan. A
CICLOSPORIN. What are the aims of this leaflet?
CICLOSPORIN What are the aims of this leaflet? This leaflet has been written to help you understand more about ciclosporin. It tells you what it is, how it works, how it is used to treat skin conditions,
LEFLUNOMIDE (Adults)
Shared Care Guideline DRUG: Introduction: LEFLUNOMIDE (Adults) Indication: Disease modifying drug for rheumatoid arthritis and psoriatic arthritis Licensing Information: Disease modifying drug for active
Rheumatoid Arthritis
Rheumatoid Arthritis While rheumatoid arthritis (RA) has long been feared as one of the most disabling types of arthritis, the outlook has dramatically improved for many newly diagnosed patients. Certainly
Markham Stouffville Hospital
Markham Stouffville Hospital Adult Diabetes Education Frequently Asked Questions What is diabetes? Diabetes is a disease in which blood glucose levels are above normal. Most of the food we eat is turned
Guideline on the management of psoriasis in South Africa
Guideline on the management of psoriasis in South Africa N Raboobee (Chair of Working Group), J Aboobaker, H F Jordaan, W Sinclair, J M Smith, G Todd, R Weiss, D Whitaker, Working Group of the Dermatological
Case Scenarios. Case Scenario 1 Group A
Case Scenarios Prior to the workshop please work through the following scenario and be prepared to present this to the rest of the group. You can work in groups of 3-4. Specialist nurses, phototherapy
Winter 2013. Changing landscapes, pipeline products and plan sponsor impact
Winter 2013 Changing landscapes, pipeline products and plan sponsor impact Changing landscapes, pipeline products and plan sponsor impact The pharmaceutical landscape is changing as is the profile of blockbuster
Sponsor Novartis. Generic Drug Name Secukinumab. Therapeutic Area of Trial Psoriasis. Approved Indication investigational
Clinical Trial Results Database Page 2 Sponsor Novartis Generic Drug Name Secukinumab Therapeutic Area of Trial Psoriasis Approved Indication investigational Clinical Trial Results Database Page 3 Study
F r e q u e n t l y A s k e d Q u e s t i o n s
Acne who specializes in treating skin problems) about how you can help prevent acne and if treatment would help you. Q: What is acne? A: Acne is a disorder that causes outbreaks of skin lesions commonly
NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum
OVERVIEW OF THE FELLOWSHIP The goal of the AASLD NP/PA Fellowship is to provide a 1-year postgraduate hepatology training program for nurse practitioners and physician assistants in a clinical outpatient
Adalimumab for the treatment of psoriasis
DOI: 10.3310/hta13suppl2/07 Health Technology Assessment 2009; Vol. 13: Suppl. 2 Adalimumab for the treatment of psoriasis D Turner, J Picot,* K Cooper and E Loveman Southampton Health Technology Assessments
Additional information >>> HERE <<< How To scalp psoriasis treatment philippines Scam or Work?
Additional information >>> HERE http://urlzz.org/psoriasis7/pdx/fph1
Leukocytoclastic Vasculitis and Stasis Dermatitis With Id Reaction
Id Reaction December 01, 2007 By David L. Kaplan, MD [1] A Photo Quiz to Hone Dermatologic Skills Case 1: A slightly pruritic eruption developed on the lower legs of a 39-year-old woman after she had an
Jerry Bagel, MD of Windsor Dermatology Home of the Psoriasis Treatment Center of Central New Jersey
JULY 2012 Jerry Bagel, MD of Windsor Dermatology Home of the Psoriasis Treatment Center of Central New Jersey Restoring Quality of Life for Psoriatic Patients Throughout NJ and Beyond Jerry Bagel, MD of
SQUAMOUS CELL CARCINOMA
SQUAMOUS CELL CARCINOMA What are the aims of this leaflet? This leaflet has been written to help you understand more about squamous cell carcinomas of the skin. It tells you what they are, what causes
